a developer of novel therapeutic compounds for diabetes and other diseases
Industry Biotechnology
A.I.dvisor tells us that DMAC and MCRB have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DMAC and MCRB's prices will move in lockstep.
Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
---|---|---|---|---|
DMAC | 100% | -1.02% | ||
MCRB - DMAC | 27% Poorly correlated | -2.16% | ||
PCVX - DMAC | 26% Poorly correlated | +36.39% | ||
SCPH - DMAC | 26% Poorly correlated | -2.75% | ||
ARVN - DMAC | 25% Poorly correlated | -2.52% | ||
CDXS - DMAC | 25% Poorly correlated | -1.38% | ||
More |
Ticker / NAME | Correlation To DMAC | 1D Price Change % |
---|---|---|
DMAC | 100% | -1.02% |
diabetes theme (4 stocks) | 55% Loosely correlated | +8.86% |
biotechnology theme (248 stocks) | 19% Poorly correlated | +5.56% |
drugs theme (265 stocks) | 19% Poorly correlated | +5.37% |
novel medical theme (11 stocks) | 15% Poorly correlated | -0.49% |